Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Atrioventricular block first degree? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Atrioventricular block first degree have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

13
Reports of Atrioventricular block first degree with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
6
Deaths
7
Hospitalizations

How Dangerous Is Atrioventricular block first degree From PEMBROLIZUMAB?

Of the 13 reports, 6 (46.2%) resulted in death, 7 (53.8%) required hospitalization, and 2 (15.4%) were considered life-threatening.

Is Atrioventricular block first degree Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Atrioventricular block first degree?

FINGOLIMOD (285) AMLODIPINE (148) METOPROLOL (120) BISOPROLOL (98) FLECAINIDE (98) OMEPRAZOLE (94) AMIODARONE (85) VERAPAMIL (84) DILTIAZEM (79) FUROSEMIDE (78)

Which PEMBROLIZUMAB Alternatives Have Lower Atrioventricular block first degree Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Atrioventricular block first degree Reports All Drugs Causing Atrioventricular block first degree PEMBROLIZUMAB Demographics